Over the last decade we have witnessed a dramatic evolution in the treatment paradigm for patients with advanced non-small cell lung cancer (NSCLC). In this, targeted therapy has become the standard of care for subgroups of patients harboring specific oncogenic driver alterations. To facilitate an accurate and timely detection of these targetable molecular alterations, hospitals have adopted different strategies to optimize the molecular testing for patients with NSCLC. In this article, Prof. Christophe Dooms (thoracic oncologist), Prof. Birgit Weynand (pathologist) and Prof. Isabelle Vanden Bempt (clinical biologist) discuss how they addressed the challenges posed by the evolving molecular testing needs in patients with NSCLC.
In this interview Prof. Dooms, Prof. Weynand and Prof. Vanden Bempt shared their insights on the following questions:
This material is meant only for individuals allowed by law to prescribe or deliver medicines.
Copyright 2023 | PP-SE-BE-0148 OCTOBER 2023
RP: Eli Lilly Benelux – Markiesstraat 1/4B Rue du Marquis, 1000 Brussel/Bruxelles